![]() Since launched, more than 1,500 patients have been treated with Yescarta in the US and Europe. Laura Hamill, executive vice president of worldwide commercial operations for Gilead, said Yescarta’s worldwide sales were $93m (€83m) during the first quarter, up 90% quarter-over-quarter. ![]() Gilead recently expanded Kite’s manufacturing capability with a new 20-acre facility in Maryland, in which the commercial production is expected to begin by late 2021.ĭominique Tonelli, head of medical affairs in Europe for Kite recently revealed to us that the company’s is producing 97% of Yescarta treatments to specification, placing the company one step ahead of Novartis, which has previously faced difficulties in effectively manufacturing its CAR-T cell therapy Kymriah (tisagenlecleucel). The company’s CFO, Robin Washington, announced $5.2bn (€4.64bn) product sales during the first quarter, a 4% increase from the same period of 2018 and down 8% sequentially. “Let's make sure we win in cell therapy and leverage the remaining parts of the Gilead focus on oncology to win in the broader oncology market as well,” he said. I think we have a leadership position, but I think we need to maintain that leadership position,” he noted and added that Kite as an independent business unit “will wake up and go to sleep every day thinking about how to be the leaders in oncology cell therapy.”Īccording to O’Day, “cell therapy is a critical piece of the puzzle with regards to the long-term future of oncology and a critical element of Gilead's long-term strategy, helping us to build on a legacy of transformational medicines.” “Kite itself in cell therapy oncology is an ultra-competitive area. Gilead’s CEO said that providing Kite with autonomy will foster agility, innovation and entrepreneurialism and added that the decision for the separation was made “for the reasons of focus.” Gilead has initiated a search for a new CEO of Kite, who will be reporting to O’Day and “will have full accountability for all aspects of cell therapy,” O’Day said. The separation had been announced internally at the end of March. ![]() Kite focuses on chimeric antigen receptor (CAR)-T cell therapies manufacturing and currently markets Yescarta (axicabtagene ciloleucel), one of the two CAR-T cell therapies approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Kite’s Tecartus CAR T-cell Therapy Demonstrates 78 Complete Response Rate and 90 Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory. During a first-quarter earnings conference call, Daniel O’Day, former Roche Pharmaceuticals CEO who took Gilead’s helm in March, announced the plan to separate Kite Pharma, which Gilead acquired in 2017 for $11,9bn (€10.6bn). Kite Announces Completion of Marketing Authorization Transfer for Yescarta CAR T-cell Therapy in Japan.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |